Articles tagged with Colitis
Researchers at UT MD Anderson Cancer Center have made significant breakthroughs in cancer treatment, developing a targeted antibody that improves outcomes for patients with advanced lung cancer who have faced treatment resistance. The treatment, which combines ivonescimab with chemotherapy, has been shown to extend disease control and ...
Researchers have mapped cellular differences between two similar bowel diseases, identifying hidden immune activity that may explain why one carries a much higher risk of colon cancer. The study found that patients with PSC-associated IBD had a distinct microbiome and higher levels of immune activity even in the absence of inflammation.
Researchers identified a link between B cell activity and immunotherapy-related colitis, a common side effect of cancer treatments. Higher B cell levels before treatment were associated with increased colitis risk, and depleting B cells reduced colitis severity.
Researchers found that nearly 77% of patients treated with fecal microbiota transplantation (FMT) experienced improvements in symptoms, with 8 of 10 patients remaining in remission. FMT may offer a quick and effective treatment to mitigate immunosuppressive treatment complications and restore a healthier balance of gut bacteria.
A study found that a bacterial enzyme BvDPP4, produced by gut microbes, weakens a protective intestinal signal GLP-2, aggravating colitis in a preclinical model. Inhibiting BvDPP4 with theaflavin improved colitis symptoms.
Researchers at the University of Gothenburg identified a link between specific gut bacteria activities and primary sclerosing cholangitis, a rare chronic liver disease. Elevated levels of the metabolite ImP, formed by gut bacteria breakdown, can predict poorer survival outcomes and induce liver inflammation in PSC patients.
A Swedish registry study found that IBD patients with multiple close relatives having colorectal cancer are significantly more likely to develop the disease. The study suggests that future cancer screening guidelines should consider the number of cancer cases in a patient's family.
A preliminary study by Weill Cornell Medicine investigators found that antifungal therapy can reduce IBD symptoms and improve the gut microbiome in patients with Candida overgrowth. The study compared the effects of two weeks of treatment with nystatin or fluconazole in 53 patients with mild-to-moderate Crohn's disease or ulcerative co...
A new review article discusses how artificial intelligence can predict disease trajectories and enable precision medicine strategies for inflammatory bowel disease. AI-based systems can standardize interpretation of endoscopic images, detect mucosal healing, and support recognition of dysplasia in patients with long-standing colitis.
Researchers found that patients with inflammatory bowel disease (IBD) are at a significantly higher risk of developing psychiatric disorders, particularly depression and anxiety. The study highlights the importance of early screening and integration of psychological care into routine IBD management to improve quality of life.
Researchers identified unique antibody signatures against viruses and bacteria in nearly 2,000 blood samples collected over a decade, showing immune system changes years before diagnosis. The study supports the theory of molecular mimicry and provides an important framework for understanding IBD's earliest stages.
A new study found that beef protein worsens gut inflammation in mice with IBD, while pea protein shows protective effects. The research suggests that dietary protein source plays a key role in shaping gut health.
A team of researchers has identified a distinct blood protein pattern that can accurately diagnose pediatric inflammatory bowel disease and differentiate between its two main forms. The discovery, using proteomics technology, showed high accuracy in identifying IBD and distinguishing ulcerative colitis from Crohn's disease.
Researchers discovered Paneth cell metaplasia can act as a protective response in ulcerative colitis by promoting healing and regeneration of the intestinal lining through REG3A. However, persistent changes may still carry risks, including increased cancer risk.
Researchers have developed a new combination therapy that shows promising results in treating patients with Crohn's disease and ulcerative colitis. The treatment, which combines two mechanisms of action, has been shown to improve clinical remission rates by more than 20 percentage points compared to existing therapies.
Researchers have identified three previously unknown genotypes of Helicobacter bacteria in pygmy sperm whales stranded along the southeastern US coast. The discovery raises new questions about microbial pathogens on ocean health and their impact on vulnerable species.
Researchers found that mice without the ANGPTL4 gene were protected from intestinal inflammation and colon tumors due to altered macrophage behavior. The study suggests that early-life inflammatory events can shape long-term immune programming, providing resistance to future challenges.
Insilico Medicine presents three abstracts at the 2026 Crohn's & Colitis Congress highlighting clinical, preclinical safety, and efficacy data for ISM5411. The first-in-human Phase 1 results show no serious adverse events or deaths reported, with a favorable pharmacokinetic profile supporting gut restriction.
A new international study found significant changes in gut bacteria at the onset of inflammatory bowel disease (IBD), a condition that affects the digestive system. The study reveals a loss of beneficial anaerobic bacteria and an increase in oxygen-tolerant bacteria, which may trigger inflammation.
The Algae for Health in Food and Pharma summit explores the latest developments in algae cultivation and processing, food innovation, and pharmaceutical applications. The event aims to advance the understanding of algae's health potential and highlight its applications across the food and pharmaceutical sectors.
Researchers discovered a new enzyme produced by Bacteroides fragilis that activates pain signaling. The enzyme is targeted with nanoparticles to develop treatments for gut pain in inflammatory bowel disease and irritable bowel syndrome. The studies aim to restore balance between good and bad bacteria to reduce symptoms.
The Crohn's & Colitis Foundation has launched GLIDE, an integrated global registry to connect patient data from IBD registries worldwide. This initiative aims to accelerate insights into complex clinical questions, driving improvements in care for those living with Crohn's disease and ulcerative colitis.
A new study published in Molecular Nutrition and Food Research found that red meat consumption causes an imbalance of bacteria in the intestinal microbiota, leading to exacerbated colonic inflammation. The diets resulted in a decrease in beneficial bacterial strains and an increase in pro-inflammatory cells.
Researchers at ETH Zurich and Stanford University quantified the number of molecules produced by gut bacteria that reach the human body daily. This knowledge helps understand how the gut microbiome influences health and behavior.
Researchers discovered pyruvate's ability to block TNFα/NF-κB signaling and directly target cytosolic phospholipase A2 (cPLA2), revealing a novel mechanism of action. This finding positions pyruvate as a unique, multifunctional therapeutic candidate for ulcerative colitis and potentially other inflammatory diseases.
A study by University of California, Riverside researchers found that inhaling agricultural dust can alter the gut microbiome and impair intestinal function, leading to increased 'leaky gut' and associated chronic diseases. The study highlights the need for protective measures for agricultural workers.
A large-scale study found no association between medication use and the development of microscopic colitis, contradicting previous findings. SSRIs were linked to a slightly higher risk, but also increased the likelihood of receiving a colonoscopy.
A study has discovered a connection between ferroptosis, a type of iron-dependent cell death, and inflammatory bowel disease. Lipid ROS activate ferroptosis, which drives cell death in the colon lining, and inhibiting this process may lead to new treatment options for IBD.
Damage to the intestinal barrier is a key factor in IBD pathogenesis. The barrier maintains homeostasis by preventing harmful substances from entering systemic circulation. Emerging therapeutic strategies target oxidative stress modulation, microbiota restoration, and autophagy regulation.
Researchers have discovered that supplementing with isobutyrate eases intestinal inflammation and restores gut balance in a pig model of colitis. The study shows that isobutyrate shifts the microbiome toward beneficial bacteria, reduces diarrhea and bleeding, and strengthens the intestinal barrier.
Microscopic colitis is a chronic inflammatory condition characterized by watery diarrhea and distinctive histologic features. The two primary subtypes are collagenous colitis and lymphocytic colitis, with collagenous colitis showing a stronger female predominance.
A pioneering research brings psychedelic medicine into gastroenterology, exploring psilocybin's effects on treatment-resistant irritable bowel syndrome (IBS). Dr. Erin E. Mauney's study modulates interoception and uses integrated therapy sessions with neuroimaging to track brain changes.
A global study describes four distinct stages of inflammatory bowel disease (IBD) as it spreads to newly developing regions in Africa, Asia, and Latin America. The research provides resources and guidance for local healthcare systems coping with the growing burden of IBD patients.
Researchers find inhibiting TMEM219 signaling restores mucosal healing in inflammatory bowel diseases and protects intestinal stem cells from death. The study suggests TMEM219 overactivation induces intestinal stem cell death, preventing mucosal renewal during inflammation.
Researchers from UCalgary and Chinese University of Hong Kong found that IBD progresses through four predictable epidemiological stages as it spreads globally. The study forecasts a major rise in IBD prevalence in Canada by 2045, with countries in North America, Europe, and Oceania reaching Stage 3 (compounding prevalence). Developing ...
Repeated esophagogastroduodenoscopy and colonoscopy enhance lesion detection, particularly in cases with active bleeding or poor visualization. The diagnostic accuracy of these procedures increases patient outcomes.
A new study published in the Journal of Crohn's and Colitis reveals that vancomycin may be an effective treatment for people with inflammatory bowel disease (IBD) and autoimmune liver disease. The antibiotic achieved clinical remission in 80% of patients, with significant decreases in inflammatory markers and mucosal healing.
Crohn's & Colitis Congress showcases cutting-edge research on IBD treatment barriers, genetic factors, and cardiovascular safety. Key studies reveal significant financial sacrifices made by patients to access care and identify epigenetic clues for Crohn's disease development.
Scientists at Tel Aviv University successfully transport mRNA-based drugs to the immune system of small and large intestines without passing through the liver. The breakthrough could enable treatments for inflammatory diseases such as Crohn's and colitis.
Researchers have reviewed the therapeutic potential of extracellular vesicles derived from mesenchymal stem cells in treating inflammatory bowel disease. The study highlights the immunomodulatory, pro-regenerative, and anti-apoptotic properties of these vesicles, which may offer a safer alternative to conventional therapies.
The American Gastroenterological Association (AGA) has released a new clinical guideline on the pharmacological management of moderate-to-severe ulcerative colitis. The guideline groups available treatments into 'efficacy buckets' to facilitate personalized treatment planning, taking into account patient risk factors and disease severity.
A study published in Food Innovation and Advances found that M3G supplementation improved colonic mucosal barrier function, reducing inflammation and increasing physical barrier strength. The compound inhibited the over-activation of the Notch signaling pathway, suggesting its potential therapeutic application for intestinal health.
Researchers from USTC identified a causal link between microbial regulation and colitis exacerbation, proposing a treatment approach by blocking the enterococcus-tyramine-ADRA2A axis. This study provides new ways for treating inflammatory bowel disease.
A groundbreaking IBD study aims to identify biomarkers for personalized treatment, monitoring, and prediction. Researchers will collect genomic data from 1,000 newly diagnosed patients in the UK over four years.
The study reveals that 5S-Heudelotinone regulates the immune system by reducing pro-inflammatory immune cell numbers, maintaining intestinal mucosal integrity by modulating tight junctions. It also increases short-chain fatty acids and alters gut microbiota diversity, highlighting its potential as a novel treatment for IBD and CAC.
Research suggests that microbes in the human gut influence social behavior, with certain bacteria offering protection against intestinal problems. The study found specific species of Blautia and Bacteroides uniformis that may benefit people with autism and GI disorders.
Researchers revealed the biological mechanisms by which class II HDACs activate Th17 cell differentiation, leading to inflammation. A potent inhibitor, TMP269, was found to influence Th17 cell differentiation in a mouse model of ulcerative colitis, providing potential therapeutic approach for IBD treatment.
A new study using spatial transcriptomics has generated a unique spatial atlas of intestinal cells in both healthy and inflamed states. The research reveals the evolution of cell populations during inflammation, particularly highlighting the significance of fibroblasts in response to gut inflammation.
Researchers at MBL have found a genetic arrangement that confers antibiotic resistance to the bacterium Bacteroides fragilis, which may help it protect itself from tetracycline. The study highlights the role of transposons in horizontal gene transfer and potential mechanisms for controlling gene expression.
The American Gastroenterological Association has proposed a 12-point plan to enhance IBD care in the US, focusing on insurer-mandated barriers such as prior authorization and step therapy. The plan aims to improve treatment access and quality for over three million Americans living with IBD.
Researchers at University of Tsukuba discovered a correlation between hypoxia levels and clinical symptoms in UC patients. Lower oxygen saturation in the rectal mucosa was associated with greater severity of colitis, making this method a potential tool for objective measurement of disease activity.
Cancer immunotherapy can cause severe colitis due to hyper-activated immune T cells and deleted regulatory T cells. Researchers at Michigan Medicine have identified a new mouse model that develops colitis after treatment with antibodies used for tumor immunotherapy, revealing the mechanism behind this side effect.
A new study finds that 10% of patients with microscopic colitis are unaware of their diagnosis, while 15% of those without the condition were unsure or thought they had it. Despite this, many cases remain symptomatic and undertreated, emphasizing the importance of follow-up appointments and education.
Researchers have developed a new method, SECRE, to identify genetic regulators of cytokine secretion in autoimmune diseases. The technique has been validated on cells known to play a crucial role in inflammatory bowel disease (IBD) and shows promising results for treating conditions with few therapeutic options.
A study published in mSystems found that mice fed a broccoli sprout diet had milder disease symptoms and richer gut microbial communities compared to those not exposed. The researchers suggest that broccoli sprouts could be used as a treatment strategy for patients with IBD.
Researchers have characterised a specialised type of immune cell that plays a key role in protecting and repairing the healthy human gut. Depletion of these cells is linked to inflammatory bowel disease (IBD) progression, with potential implications for treatment options.
Nearly 70% of adolescents and young adults with ulcerative colitis discontinue treatment within a year of diagnosis, putting them at risk of disease relapse. The study highlights the need for active follow-up by GPs to monitor medication adherence and affordability.
Researchers developed a platform that allows engineered biosensor bacteria to safely pass through the gastrointestinal tract in animal models. The platform enables real-time monitoring of gut health and can be used to diagnose and monitor various diseases, including inflammatory bowel disease. It has the potential to revolutionize pati...
Researchers found that a diet high in soybean oil decreases beneficial bacteria and increases harmful bacteria, leading to increased inflammation and susceptibility to colitis. Olive oil, with lower amounts of linoleic acid, is considered a healthier alternative.
A UNIGE team has developed small beads encapsulating fecal bacteria for treating a serious intestinal infection. The technology overcomes obstacles in current treatments, allowing for easier and more comfortable administration.